Mass Spectrometry an Essential Tool for Characterisation of Monoclonal Antibodies During Development
Posted on June 20, 2022
Wei Xu, Director of Analytical Development, Therapeutic Proteins & Vaccines, AstraZeneca
Therapeutic proteins produced in cells using recombinant DNA technology are highly effective and have fewer side effects than small molecule drugs1, 2. Specifically, recombinant monoclonal antibodies (mAb) represent a large portion of therapeutic proteins. The sales of mAbs accounted 51.8% of the $1...
To read the full article and other articles in this issue, please register for a free account or log in.
We will not sell or give your information to a third party. See our Privacy Policy
Subscribe to our FREE newsletter
We will not sell or give your information to a third party. See our Privacy Policy